Méndez-Eirín Elizabet, Flores-Ríos Xacobe, García-López Fernando, Pérez-Pérez Alberto J, Estévez-Loureiro Rodrigo, Piñón-Esteban Pablo, Aldama-López Guillermo, Salgado-Fernández Jorge, Calviño-Santos Ramón A, Vázquez Rodríguez José M, Vázquez-González Nicolás, Castro-Beiras Alfonso
Unidad de Hemodinámica, Servicio de Cardiología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):227-33. doi: 10.1016/j.recesp.2011.10.019. Epub 2012 Jan 26.
We sought to compare the predictive value of the Thrombolysis In Myocardial Infarction (TIMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC), Primary Angioplasty in Myocardial Infarction (PAMI), and Global Registry for Acute Coronary Events (GRACE) scores for the outcome of ST-segment elevation acute coronary syndrome undergoing urgent percutaneous coronary intervention.
We performed a retrospective analysis of a cohort composed of all consecutive patients with ST-segment elevation acute coronary syndrome treated by urgent percutaneous coronary intervention between 2006 and 2010 (n=1503). TIMI, PAMI, CADILLAC, and GRACE risk scores were calculated for each patient according to different clinical variables. We assessed the predictive accuracy of these scores for death, reinfarction, and target-vessel revascularization at 30 days and 1 year, using the C statistic, which was obtained by means of logistic regression and ROC curves.
The TIMI, PAMI, CADILLAC and GRACE showed an excellent predictive value for 30-day and 1-year mortality (C statistic range, 0.8-0.9), with superiority of the TIMI, CADILLAC, and GRACE risk models. The performance of these 4 scores was poor for both reinfarction and target-vessel revascularization (C statistic, 0.5-0.6).
The TIMI, PAMI, CADILLAC, and GRACE scores provide excellent information to stratify the risk of mortality in patients treated by percutaneous coronary intervention. The TIMI, CADILLAC, and GRACE models have higher predictive accuracy. The usefulness of these models for reinfarction and target-vessel revascularization prediction is questionable.
我们旨在比较心肌梗死溶栓治疗(TIMI)、抑制血小板糖蛋白Ⅱb/Ⅲa受体的单克隆抗体阿昔单抗对照和降低晚期血管成形术并发症器械研究(CADILLAC)、心肌梗死直接血管成形术(PAMI)以及急性冠状动脉事件全球注册研究(GRACE)评分对接受紧急经皮冠状动脉介入治疗的ST段抬高型急性冠状动脉综合征患者预后的预测价值。
我们对2006年至2010年间接受紧急经皮冠状动脉介入治疗的所有连续性ST段抬高型急性冠状动脉综合征患者组成的队列进行了回顾性分析(n = 1503)。根据不同临床变量为每位患者计算TIMI、PAMI、CADILLAC和GRACE风险评分。我们使用通过逻辑回归和ROC曲线获得的C统计量评估这些评分对30天和1年时死亡、再梗死和靶血管血运重建的预测准确性。
TIMI、PAMI、CADILLAC和GRACE对30天和1年死亡率显示出优异的预测价值(C统计量范围为0.8 - 0.9),TIMI、CADILLAC和GRACE风险模型更具优势。这4种评分对再梗死和靶血管血运重建的预测表现均较差(C统计量为0.5 - 0.6)。
TIMI、PAMI、CADILLAC和GRACE评分可为经皮冠状动脉介入治疗患者的死亡风险分层提供优异信息。TIMI、CADILLAC和GRACE模型具有更高的预测准确性。这些模型对再梗死和靶血管血运重建预测的实用性值得怀疑。